News | April 21, 2014

Robert Wood Johnson Treats Calcified Lesions Transradially

April 21, 2014 — Treatment options for high-risk heart patients with severely calcified coronary artery disease (CAD) have been limited for more than 20 years. Now, Robert Wood Johnson University Hospital (RWJUH) in New Brunswick, N.J., offers a new alternative to open up blocked arteries.

Plaque build-up in the arteries can form calcium lesions, and that build-up can be difficult to treat and significantly impact the quality of life of persons affected, explained Ramzan M. Zakir M.D., clinical assistant professor of medicine at Rutgers Robert Wood Johnson Medical School and director of transradial catheterization at RWJUH. For patients with lots of calcium in the arteries, it may be necessary to break up the calcium to allow the stents to open up or expand properly, he added.

“Although a device to break up calcium exists, that same device hasn’t really changed in over 20 years. It’s complex to use and involves a lengthy set-up time, leading some physicians to opt for open heart surgery to treat such blockages,” he said. “With the recently FDA-approved device called the Diamondback 360, we can easily break up the calcium to facilitate stent delivery and proper expansion. Even complex cases that previously could only be treated through the femoral artery now can be treated radially to restore proper blood flow and relieve patients’ symptoms such as chest pain and shortness of breath.”

Zakir has completed the required training, including six cases, for use of the Diamondback 360 Coronary Orbital Atherectomy System and is now the first physician in New Jersey to receive coronary certification from device maker Cardiovascular Systems Inc. (CSI).

This new, less invasive treatment alternative is significantly important for patients with severely calcified coronary artery disease that are considered high risk, including those managing other diseases (such as diabetes and chronic kidney disease) or the elderly, Zakir said.

CAD occurs when a fatty material called plaque builds up on the walls of arteries that supply blood to the heart. The plaque buildup causes the arteries to harden and narrow (atherosclerosis), reducing blood flow. CAD is a life-threatening condition and leading cause of death in men and women in the United States.

The risk of CAD increases if a person has one or more of the following: high blood pressure, abnormal cholesterol levels, diabetes, or family history of early heart disease. CAD affects an estimated 17 million people in the United States and is the most common form of heart disease, which claims more than 600,000 lives in the United States each year.

According to estimates, significant arterial calcium is present in nearly 40 percent of patients undergoing a percutaneous coronary intervention (PCI). Significant calcium contributes to poor outcomes and higher treatment costs in coronary interventions when traditional therapies are used, including a significantly higher occurrence of death and major adverse cardiac events.

Cardiovascular Systems Inc. received U.S. Food and Drug Administration (FDA) approval for the Diamondback 360 in October and RWJUH is one of only two hospitals in New Jersey using it.

For more information:,

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init